T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy

References

• Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011; 17(13):4568-80; PMID:21586625; http://dx.doi.org/10.1158/1078-0432.CCR-11-0184
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, Moller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17(21):6847-57; PMID:21918169; http://dx.doi.org/10.1158/1078-0432.CCR-11-1385
   PubMed Web of Science ®Google Scholar
• Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Moller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother 2011; 60(11):1553-64; PMID:21681371; http://dx.doi.org/10.1007/s00262-011-1061-z
   PubMed Web of Science ®Google Scholar
• Bernhardt SL, Gjertsen MK, Trachsel S, Moller M, Eriksen JA, Meo M, Buanes T, Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006; 95(11):1474-82; PMID:17060934; http://dx.doi.org/10.1038/sj.bjc.6603437
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266(5193):2011-5; PMID:7605428; http://dx.doi.org/10.1126/science.7605428
   PubMed Web of Science ®Google Scholar
• Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8:167-79; PMID:18256617; http://dx.doi.org/10.1038/nrc2275
   PubMed Web of Science ®Google Scholar
• Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunol Immunother 2015; 64(12):1609-21; PMID:26498005; http://dx.doi.org/10.1007/s00262-015-1766-5
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Moller M, Eriksen JA et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55(12):1553-64; PMID:16491401; http://dx.doi.org/10.1007/s00262-006-0145-7
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368(16):1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa1215134
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6(224):224ra225; PMID:24553386; http://dx.doi.org/10.1126/scitranslmed.3008226
   Web of Science ®Google Scholar
• Abken H. Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. Immunotherapy 2015; 7(5):535-44; PMID:26065478; http://dx.doi.org/10.2217/imt.15.15
   PubMed Web of Science ®Google Scholar
• Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther 2016; 24:1135-49; PMID:27019998; http://dx.doi.org/10.1038/mt.2016.63
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384(9948):1109-17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373(1):23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015; 21(4):712-20; PMID:25524312; http://dx.doi.org/10.1158/1078-0432.CCR-14-2468
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300(5617):337-9; PMID:12690201; http://dx.doi.org/10.1126/science.1082305
   PubMed Web of Science ®Google Scholar
• Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421(6925):852-6; PMID:12594515; http://dx.doi.org/10.1038/nature01441
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54(8):721-8; PMID:16010587; http://dx.doi.org/10.1007/s00262-004-0653-2
   PubMed Web of Science ®Google Scholar
• Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494(7437):361-5; PMID:23376950; http://dx.doi.org/10.1038/nature11824
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003; 9(3):998-1008; PMID:12631598
   PubMed Web of Science ®Google Scholar
• Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, Coulie PG, Boon T. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201(2):249-57; PMID:15657294; http://dx.doi.org/10.1084/jem.20041378
   PubMed Web of Science ®Google Scholar
• Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 2012; 1(5):670-86; PMID:22934259; http://dx.doi.org/10.4161/onci.20426
   PubMed Web of Science ®Google Scholar
• Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011; 60(6):809-18; PMID:21365467; http://dx.doi.org/10.1007/s00262-011-0991-9
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348(6230):124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348(6230):69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351:1463-9; PMID:26940869; http://dx.doi.org/10.1126/science.aaf1490
   PubMed Web of Science ®Google Scholar
• Andersen RS, Andersen SR, Hjortso MD, Lyngaa R, Idorn M, Kollgard TM, Met O, Thor Straten P, Hadrup SR. High frequency of T cells specific for cryptic epitopes in melanoma patients. Oncoimmunology 2013; 2(7):e25374; PMID:24073381; http://dx.doi.org/10.4161/onci.25374
   Google Scholar
• Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012; 1(4):409-18; PMID:22754759; http://dx.doi.org/10.4161/onci.18851
   PubMed Web of Science ®Google Scholar
• Kyte JA, Trachsel S, Risberg B, Thor Straten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother 2009; 58(10):1609-26; PMID:19221745; http://dx.doi.org/10.1007/s00262-009-0670-2
   PubMed Web of Science ®Google Scholar
• Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C, Gahery-Segard H, Guillet JG, Menez A, Georges B et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 2002; 169(12):6928-34; PMID:12471126; http://dx.doi.org/10.4049/jimmunol.169.12.6928
   PubMed Web of Science ®Google Scholar
• Walchli S, Loset GA, Kumari S, Johansen JN, Yang W, Sandlie I, Olweus J. A practical approach to T-cell receptor cloning and expression. PloS one 2011; 6(11):e27930; PMID:22132171; http://dx.doi.org/10.1371/journal.pone.0027930
   PubMedGoogle Scholar
• Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, Marin V, Marafioti T, Chakraverty R, Linch D et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 2014; 124(8):1277-87; PMID:24970931
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73(1):19-29; PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127
   PubMed Web of Science ®Google Scholar
• Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006; 440(7086):890-5; PMID:16612374; http://dx.doi.org/10.1038/nature04651
   PubMed Web of Science ®Google Scholar
• Malandro N, Budhu S, Kuhn NF, Liu C, Murphy JT, Cortez C, Zhong H, Yang X, Rizzuto G, Altan-Bonnet G et al. Clonal abundance of tumor-specific CD4(+) T cells potentiates efficacy and alters susceptibility to exhaustion. Immunity 2016; 44(1):179-93; PMID:26789923; http://dx.doi.org/10.1016/j.immuni.2015.12.018
   PubMed Web of Science ®Google Scholar
• Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol 2014; 44(1):69-79; PMID:24114780; http://dx.doi.org/10.1002/eji.201343718
   PubMed Web of Science ®Google Scholar
• Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358(25):2698-703; PMID:18565862; http://dx.doi.org/10.1056/NEJMoa0800251
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344(6184):641-5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
   PubMed Web of Science ®Google Scholar
• Kayser S, Bobeta C, Feucht J, Witte KE, Scheu A, Bulow HJ, Joachim S, Stevanovic S, Schumm M, Rittig SM et al. Rapid generation of NY-ESO-1-specific CD4 T1 cells for adoptive T-cell therapy. Oncoimmunology 2015; 4(5):e1002723; PMID:26155389; http://dx.doi.org/10.1080/2162402X.2014.1002723
   Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39(1):74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol 2012; 24(5):633-9; PMID:22818942; http://dx.doi.org/10.1016/j.coi.2012.06.004
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014; 2(2):112-20; PMID:24579088; http://dx.doi.org/10.1158/2326-6066.CIR-13-0170
   PubMed Web of Science ®Google Scholar
• Almasbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G et al. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther 2015; 22(5):391-403; PMID:25652098; http://dx.doi.org/10.1038/gt.2015.4
   PubMed Web of Science ®Google Scholar
• Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood 2015; 125(26):4103-13; PMID:25977584; http://dx.doi.org/10.1182/blood-2015-02-628354
   PubMed Web of Science ®Google Scholar
• Donia M, Andersen R, Kjeldsen JW, Fagone P, Munir S, Nicoletti F, Andersen MH, Thor Straten P, Svane IM. Aberrant expression of MHC class II in melanoma attracts inflammatory tumor-specific CD4+ T-cells, which dampen CD8+ T-cell antitumor reactivity. Cancer Res 2015; 75(18):3747-59; PMID:26183926; http://dx.doi.org/10.1158/0008-5472.CAN-14-2956
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Palma M, Hansson L, Osterborg A, Mellstedt H, Choudhury A.88 Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007; 35(2):297-304; PMID:17258078; http://dx.doi.org/10.1016/j.exphem.2006.10.006
   PubMed Web of Science ®Google Scholar
• Vigano S, Utzschneider DT, Perreau M, Pantaleo G, Zehn D, Harari A. Functional avidity: a measure to predict the efficacy of effector T cells? Clin Dev Immunol 2012; 2012:153863; PMID:23227083; http://dx.doi.org/10.1155/2012/153863
   PubMedGoogle Scholar
• Li LP, Lampert JC, Chen X, Leitao C, Popovic J, Muller W, Blankenstein T. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med 2010; 16(9):1029-34; PMID:20693993; http://dx.doi.org/10.1038/nm.2197
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122(6):863-71; PMID:23770775; http://dx.doi.org/10.1182/blood-2013-03-490565
   PubMed Web of Science ®Google Scholar
• Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci USA 2013; 110(17):6973-8; PMID:23576742; http://dx.doi.org/10.1073/pnas.1221609110
   PubMed Web of Science ®Google Scholar
• Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107(12):4781-9; PMID:16467198; http://dx.doi.org/10.1182/blood-2005-12-4818
   PubMed Web of Science ®Google Scholar
• Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13(7):843-50; PMID:17558415; http://dx.doi.org/10.1038/nm1592
   PubMed Web of Science ®Google Scholar
• Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, Roederer M, Rowland-Jones SL, Koup RA. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008; 38(2):350-63; PMID:18200635; http://dx.doi.org/10.1002/eji.200737768
   PubMed Web of Science ®Google Scholar
• Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007; 81(16):8468-76; PMID:17553885; http://dx.doi.org/10.1128/JVI.00228-07
   PubMed Web of Science ®Google Scholar
• Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008; 105(51):20410-5; PMID:19074257; http://dx.doi.org/10.1073/pnas.0810114105
   PubMed Web of Science ®Google Scholar
• Kyte JA, Kvalheim G, Aamdal S, Saeboe-Larssen S, Gaudernack G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther 2005; 12(6):579-91; PMID:15818380; http://dx.doi.org/10.1038/sj.cgt.7700837
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Saeterdal I, Saeboe-Larssen S, Gaudernack G. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med (Berlin, Germany) 2003; 81(1):43-50; PMID:12545248
   PubMed Web of Science ®Google Scholar